셉테나 (SEPN) 주가

셉테나(SEPN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $38.69 (-2.05%), 시가총액 $1.21B, 52주 최저~최고 $9.06 ~ $30.86.

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular di

핵심 지표

• 현재가: $38.69 (-2.05%)
• 시가총액: $1.21B
• 52주 최저~최고: $9.06 ~ $30.86
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

셉테나의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

셉테나 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.25

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 2.81
• 순이익률: -0.50%
• 영업이익률: -0.50%

자주 묻는 질문